Product news from the 02/27/07 news brief
The FDA granted approval to Shire’s Vyvanse (lisdexamfetamine) as a treatment for attention deficit hyperactivity disorder (ADHD) in pediatric patients ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.